Needham Maintains a Hold Rating on Amphastar Pharmaceuticals (AMPH)

In a report released today, Serge Belanger from Needham maintained a Hold rating on Amphastar Pharmaceuticals (AMPHResearch Report). The company’s shares closed last Monday at $18.01, close to its 52-week low of $16.92.

According to TipRanks.com, Belanger is a 1-star analyst with an average return of -1.5% and a 39.6% success rate. Belanger covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals, Collegium Pharmaceutical, and Zynerba Pharmaceuticals.

Amphastar Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $20.50, implying a 7.3% upside from current levels. In a report released today, BMO Capital also maintained a Hold rating on the stock with a $21.00 price target.

See today’s analyst top recommended stocks >>

Based on Amphastar Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $47.79 million. In comparison, last year the company had a net profit of $2.39 million.

Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMPH in relation to earlier this year. Most recently, in August 2019, Richard Prins, a Director at AMPH sold 7,500 shares for a total of $169,384.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments.